title: Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.
abstract: The aim of this study was to fabricate valsartan composite nanoparticles by using the supercritical antisolvent (SAS) process, and to evaluate the correlation between in vitro dissolution and in vivo pharmacokinetic parameters for the poorly water-soluble drug valsartan. Spherical composite nanoparticles with a mean size smaller than 400 nm, which contained valsartan, were successfully fabricated by using the SAS process. X-ray diffraction and thermal analyses indicated that valsartan was present in an amorphous form within the composite nanoparticles. The in vitro dissolution and oral bioavailability of valsartan were dramatically enhanced by the composite nanoparticles. Valsartan-hydroxypropyl methylcellulose-poloxamer 407 nanoparticles exhibited faster drug release (up to 90% within 10 minutes under all dissolution conditions) and higher oral bioavailability than the raw material, with an approximately 7.2-fold higher maximum plasma concentration. In addition, there was a positive linear correlation between the pharmacokinetic parameters and the in vitro dissolution efficiency. Therefore, the preparation of composite nanoparticles with valsartan-hydroxypropyl methylcellulose and poloxamer 407 by using the SAS process could be an effective formulation strategy for the development of a new dosage form of valsartan with high oral bioavailability.
authors.affiliation: College of Pharmacy, Pusan National University, Geumjeong-gu, Busan, Republic of Korea.
authors.forename: Min-Soo
authors.initials: MS
authors.lastname: Kim
authors.affiliation: College of Pharmacy, Kyungsung University, Daeyeon-dong, Nam-gu, Busan, Republic of Korea.
authors.forename: In-Hwan
authors.initials: IH
authors.lastname: Baek
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D065347:Hypromellose Derivatives / Q000737:chemistry*; D008297:Male; D053761:Nanocomposites / Q000008:administration & dosage / Q000737:chemistry*; D036103:Nanotechnology / Q000379:methods; D020442:Poloxamer / Q000737:chemistry*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D013501:Surface-Active Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D013777:Tetrazoles / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics; D000068756:Valsartan
chemical_list: D013501:Surface-Active Agents; D013777:Tetrazoles; D020442:Poloxamer; D065347:Hypromellose Derivatives; D000068756:Valsartan; D014633:Valine
keywords: bioavailability; dissolution; solid dispersion; supercritical fluid; supersaturation